SRP-1003 Shows Nuclear DMPK RNA Knockdown
Sarepta presented new preclinical data showing that its alpha-v-beta-6 integrin-targeted siRNA SRP-1003 reduced pathogenic DMPK RNA in both nuclear and cytoplasmic compartments of DM1 patient-derived myotubes, reaching approximately 80% knockdown in each. Independent assays…
